Frequency of EGFR and KRAS mutations in patients with non small cell lung cancer by racial background: Do disparities exist?

Lung Cancer

Volumn 81, Issue 3, 2013, Pages 347-353

  Bauml, Joshua ^a   Mick, Rosemarie ^b   Zhang, Yu ^a   Watt, Christopher D ^a   Vachani, Anil ^a   Aggarwal, Charu ^a   Evans, Tracey ^a   Langer, Corey ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

EGFR; KRAS; NSCLC; Racial disparity

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; K RAS PROTEIN;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; CANCER PATIENT; CAUCASIAN; CHARLSON COMORBIDITY INDEX; CODON; CONTROLLED STUDY; ELECTRONIC MEDICAL RECORD; ETHNIC DIFFERENCE; FEMALE; GENDER; GENE MUTATION; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PRIORITY JOURNAL; RACE; SMOKING;

EGFR; KRAS; NSCLC; RACIAL DISPARITY;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; ETHNIC GROUPS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; MUTATION RATE; ODDS RATIO; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RISK FACTORS;

EID: 84881664448     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2013.05.011     Document Type: Article

References (31)

1. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012, 62(1):10-29. 10.3322/caac.20138.
2. Zhou C., Wu Y.-L., Chen G., Feng J., Liu X.-Q., Wang C., et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011, 12(8):735-742. 10.1016/S1470-2045(11)70184-X.
3. Fukuoka M., Wu Y.-L., Thongprasert S., Sunpaweravong P., Leong S.-S., Sriuranpong V., et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol: Offi J Am Soc Clin Oncol 2011, 29(21):2866-2874. 10.1200/JCO.2010.33.4235.
4. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350(21):2129-2139. 10.1056/NEJMoa040938.
5. Lee J.S., Park K., Kim S.W. A randomized phase III study of gefitinib versus standard chemotherapy (gemcitabine plus cisplatin) as a first-line treatment for never-smokers with advanced or metastatic adenocarcinoma of the lung. World Conference on Lung Cancer 2009, doi:6B768E63-9B38-45C6-BEA3-C3BCB9556889.
6. Maemondo M., Inoue A., Kobayashi K., Sugawara S., Oizumi S., Isobe H., et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010, 362(25):2380-2388. 10.1056/NEJMoa0909530.
7. Mitsudomi T., Morita S., Yatabe Y., Negoro S., Okamoto I., Tsurutani J., et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010, 11(2):121-128. 10.1016/S1470-2045(09)70364-X.
8. Rosell R., Carcereny E., Gervais R., Vergnenegre A., Massuti B., Felip E., et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012, 13(3):239-246. 10.1016/S1470-2045(11)70393-X.
9. D'Angelo S.P., Pietanza M.C., Johnson M.L., Riely G.J., Miller V.A., Sima C.S., et al. Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas. J Clin Oncol: Offi J Am Soc Clin Oncol 2011, 29(15):2066-2070. 10.1200/JCO.2010.32.6181.
10. Calvo E., Baselga J. Ethnic differences in response to epidermal growth factor receptor tyrosine kinase inhibitors. J Clin Oncol: Offi J Am Soc Clin Oncol 2006, 24(14):2158-2163. 10.1200/JCO.2006.06.5961.
11. Pao W., Miller V., Zakowski M., Doherty J., Politi K., Sarkaria I., et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004, 101(36):13306-13311. 10.1073/pnas.0405220101.
12. Marchetti A., Martella C., Felicioni L., Barassi F., Salvatore S., Chella A., et al. EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol: Offi J Am Soc Clin Oncol 2005, 23(4):857-865. 10.1200/JCO.2005.08.043.
13. Underwood J.M., Townsend J.S., Tai E., Davis S.P., Stewart S.L., White A., et al. Racial and regional disparities in lung cancer incidence. Cancer 2012, 118(7):1910-1918. 10.1002/cncr.26479.
14. Berger M., Lund M.J., Brawley O.W. Racial disparities in lung cancer. Curr Probl Cancer 2007, 31(3):202-210. 10.1016/j.currproblcancer.2007.02.002.
15. Charlson M.E., Pompei P., Ales K.L., MacKenzie C.R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987, 40(5):373-383. doi:EBD7B5DE-6D4F-49BD-836D-C55E8103B0D8.
16. Aisner D.L., Deshpande C., Baloch Z., Watt C.D., Litzky L.A., Malhotra B., et al. Evaluation of EGFR mutation status in cytology specimens: an institutional experience. Diagn Cytopathol 2011, 10.1002/dc.21851.
17. Yang S.H., Mechanic L.E., Yang P., Landi M.T., Bowman E.D., Wampfler J., et al. Mutations in the tyrosine kinase domain of the epidermal growth factor receptor in non-small cell lung cancer. Clin Cancer Res: Offi J Am Assoc Cancer Res 2005, 11(6):2106-2110. 10.1158/1078-0432.CCR-04-1853.
18. Leidner R.S., Fu P., Clifford B., Hamdan A., Jin C., Eisenberg R., et al. Genetic abnormalities of the EGFR pathway in African American patients with non-small-cell lung cancer. J Clin Oncol: Offi J Am Soc Clin Oncol 2009, 27(33):5620-5626. 10.1200/JCO.2009.23.1431.
19. Riely G.J., Pao W., Pham D., Li A.R., Rizvi N., Venkatraman E.S., et al. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res: Offi J Am Assoc Cancer Res 2006, 12(3 Pt 1):839-844. 10.1158/1078-0432.CCR-05-1846.
20. Cote M.L., Haddad R., Edwards D.J., Atikukke G., Gadgeel S., Soubani A.O., et al. Frequency and type of epidermal growth factor receptor mutations in African Americans with non-small cell lung cancer. J Thorac Oncol: Offi Publ Int Assoc Study Lung Cancer 2011, 6(3):627-630. 10.1097/JTO.0b013e31820a0ec0.
21. Reinersman J.M., Johnson M.L., Riely G.J., Chitale D.A., Nicastri A.D., Soff G.A., et al. Frequency of EGFR and KRAS mutations in lung adenocarcinomas in African Americans. J Thorac Oncol 2011, 6(1):28-31. PubMed PMID: 21107288; PubMed Central PMCID: PMC3337520. 10.1097/JTO.0b013e3181fb4fe2.
22. Sequist L.V., Joshi V.A., Jänne P.A., Muzikansky A., Fidias P., Meyerson M., et al. Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing. Oncologist 2007, 12(1):90-98. doi:7112082D-247A-474B-A8D4-86C0B9E6C204.
23. Tokumo M., Toyooka S., Kiura K., Shigematsu H., Tomii K., Aoe M., et al. The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers. Clin Cancer Res: Offi J Am Assoc Cancer Res 2005, 11(3):1167-1173. doi:F6D01F68-5DAC-4BD9-BA36-8C0530A5159B.
24. Harada T., Lopez-Chavez A., Xi L., Raffeld M., Wang Y., Giaccone G. Characterization of epidermal growth factor receptor mutations in non-small-cell lung cancer patients of African-American ancestry. Oncogene 2011, 30(15):1744-1752. 10.1038/onc.2010.545.
25. Ettinger D.S., Akerley W., Bepler G., Blum M.G., Chang A., Cheney R.T., et al. Non-small cell lung cancer. J Natl Compr Cancer Netw 2010, 8(7):740-801. doi:32AC9037-9D65-4D59-B024-E6857CBFFF18.
26. Nelson H.H., Christiani D.C., Mark E.J., Wiencke J.K., Wain J.C., Kelsey K.T. Implications and prognostic value of K-ras mutation for early-stage lung cancer in women. J Natl Cancer Inst 1999, 91(23):2032-2038. doi:D6404CFC-0A9F-4954-A516-9D0DED69CAE8.
27. Bacchi C.E., Ciol H., Queiroga E.M., Benine L.C., Silva L.H., Ojopi E.B. Epidermal growth factor receptor and KRAS mutations in Brazilian lung cancer patients. Clinics (São Paulo, Brazil) 2012, 67(5):419-424. doi:F04AA1B0-F128-493A-A47B-F45F7553371A.
28. Rouquette I., Lauwers-Cances V., Allera C., Brouchet L., Milia J., Nicaise Y., et al. Characteristics of lung cancer in women: importance of hormonal and growth factors. Lung Cancer (Amsterdam, Netherlands) 2012, 76(3):280-285. 10.1016/j.lungcan.2011.11.023.
29. Keohavong P., DeMichele M.A., Melacrinos A.C., Landreneau R.J., Weyant R.J., Siegfried J.M. Detection of K-ras mutations in lung carcinomas: relationship to prognosis. Clin Cancer Res: Offi J Am Assoc Cancer Res 1996, 2(2):411-418. doi:2191341A-2C0B-4BFC-988A-5EAF30CD76E1.
30. Yatabe Y., Matsuo K., Mitsudomi T. Heterogeneous distribution of EGFR mutations is extremely rare in lung adenocarcinoma. J Clin Oncol: Offi J Am Soc Clin Oncol 2011, 29(22):2972-2977. 10.1200/JCO.2010.33.3906.
31. Sharma S.V., Bell D.W., Settleman J., Haber D.A. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007, 7(3):169-181. 10.1038/nrc208.